One-lung Ventilation: Expression of Pulmonary Inflammatory Mediators

This study has been completed.
Sponsor:
Information provided by:
University of Zurich
ClinicalTrials.gov Identifier:
NCT00515905
First received: August 13, 2007
Last updated: September 14, 2010
Last verified: March 2008
  Purpose

One-lung ventilation; organ protection; volatile anesthetics

One-lung ventilation has become a common procedure for thoracoscopic surgery. Two hypothesis will be tested in this study:

  1. Are inflammatory mediators increased in the re-ventilated lung after short-period pulmonary collapse?
  2. Does Sevoflurane influence the production of inflammatory mediators in the re-inflated lung? Therefore, this study will elucidate the potential protective effect of a volatile anaesthetic (sevoflurane) on the production of inflammatory mediators by the respiratory compartment of the lung, i.e. the alveolar epithelium.

    • Trial with immunomodulatory product / biological

Condition Intervention
Thoracic Surgery With One-lung Ventilation
Drug: Sevoflurane/propofol

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Pharmacodynamics Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Prevention
Official Title: Lung: One-lung Ventilation: Expression of Pulmonary Inflammatory Mediators After Deflation and Re-expansion of the Lung During Thoracic Surgery

Resource links provided by NLM:


Further study details as provided by University of Zurich:

Primary Outcome Measures:
  • One-lung ventilation measurement in the re-ventilated lung after short-period pulmonary collapse [ Time Frame: Sep 07 ] [ Designated as safety issue: No ]

Estimated Enrollment: 76
Study Start Date: October 2004
Study Completion Date: September 2007
Primary Completion Date: September 2007 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: Sevoflurane/propofol
    Sevoflurane/propofol
  Eligibility

Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria:

  • Thoracic surgery (thoracotomy, thoracoscopy) with one-lung ventilation

Exclusion criteria:

  • Immunosuppressive therapy
  • Ongoing inflammatory processes
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00515905

Locations
Switzerland
University Hospital of Zurich
Zurich, Switzerland
Sponsors and Collaborators
University of Zurich
Investigators
Study Director: 01 Studienregister MasterAdmins UniversitaetsSpital Zuerich
  More Information

No publications provided

Responsible Party: Beatrice Beck-Schimmer, University of Zurich
ClinicalTrials.gov Identifier: NCT00515905     History of Changes
Other Study ID Numbers: StV 20-2004
Study First Received: August 13, 2007
Last Updated: September 14, 2010
Health Authority: Switzerland: Swissmedic

Additional relevant MeSH terms:
Sevoflurane
Platelet Aggregation Inhibitors
Hematologic Agents
Therapeutic Uses
Pharmacologic Actions
Anesthetics, Inhalation
Anesthetics, General
Anesthetics
Central Nervous System Depressants
Physiological Effects of Drugs
Central Nervous System Agents

ClinicalTrials.gov processed this record on October 19, 2014